Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about CSBR, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
CSBR holds $4.4M in cash and short-term investments (as of Jul 31, 2026) and burns about $1.2M/quarter from operations, an estimated runway of 10.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CSBR files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Joel Ackerman Director · +131,372 options |
Insider | 1,126,333 | 8.09% | 2026-10-15 |
| Daniel Newman Mendelson Director · +81,891 options |
Insider | 198,625 | 1.43% | 2024-01-12 |
| Philip P. Breitfeld Director · +48,000 options |
Insider | 5,717 | 0.04% | 2025-03-25 |
Share count 13,918,569 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CSBR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →